# Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)

> **NCT00527605** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 253 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia
- Prostatic Hyperplasia

## Interventions

- **DRUG:** Dutasteride 0.5mg capsule
- **DRUG:** Dutasteride matched placebo

## Key facts

- **NCT ID:** NCT00527605
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2012-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527605, "Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00527605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*